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ABSTRACT Three different heparin-catalyzed inhibitor/
protease reactions were studied: antithrombin Ill/thrombin, hep-
arin cofactor II/thrombin, antithrombin IE/factor Xa. The three
reactions were saturable with respect to both inhibitor and pro-
tease. The initial reaction velocity, for each reaction, could be de-
scribed by the general rate equation for a random-order bireac-
tant enzyme-catalyzed reaction. The kinetic parameters for the
heparin-catalyzed antithrombin HI/thrombin and antithrombin
II/factor Xa reactions differed in terms of apparent maximum
velocity (Vm.) and apparent heparin-protease dissociation con-
stant values. The apparent heparin-antithrombin III dissociation
constant values were the same for both reactions. The kinetic pa-
rameters for the heparin-catalyzed antithrombin III/thrombin and
heparin cofactor II/thrombin reactions differed in terms of ap-
parent Vma. and apparent heparin-inhibitor dissociation constant
values. The apparent heparin-thrombin dissociation constant val-
ues were the same for both reactions. The results are consistent
with a general mechanism of action of heparin for the three re-
actions that, in its simplest form, requires only that both protease
and inhibitor bind to heparin for catalysis to occur.
Heparin increases the rate of thrombin inhibition by antithrom-
bin III (1-3). In a recent paper, it was reported that the hepa-
rin-catalyzed antithrombin III/thrombin reaction is saturable
with respect to both thrombin and antithrombin III (4). The
initial reaction velocity, under any set of experimental condi-
tions, can be described by the general rate equation for a ran-
dom-order bireactant enzyme-catalyzed reaction, which is
mathematically identical to the "template" model for the mech-
anism of action of heparin (5, 6). In principle, the template model
for the mechanism of action of heparin implies that the binding
of both thrombin and antithrombin III to heparin is required
for the catalytic activity of heparin (7-10).
Heparin also accelerates other antithrombin III/protease re-
actions (11). By varying the heparin concentration over a rel-
atively large range, it has been shown that the kinetics of factor
IXa, factor Xa, plasmin, and thrombin inhibition by antithrom-
bin III appear to differ significantly (12). It has been suggested
(13) that "heparin possesses. multiple functional domains that
modulate different functions of antithrombin." An alternative
explanation for the apparent differences in the kinetics of the
various antithrombin III/protease reactions is that different
proteases bind to heparin with different affinities.
Thrombin is also inhibited at an increased rate in the pres-
ence of heparin by heparin cofactor II (14-18). Although it has
been shown that higher heparin concentrations are required to
observe a significant acceleration of the heparin cofactor II/
thrombin reaction as compared with the antithrombin III/
thrombin reaction (16-18), a detailed analysis of the kinetics of
the heparin-catalyzed heparin cofactor II/thrombin reaction has
not been reported.
The purpose of the present study was to evaluate the kinetics
of different heparin-catalyzed reactions to determine whether
or not a common underlying mechanism of action of heparin
exists. It has been found that the apparent catalytic activity of
heparin is related to the apparent binding affinity of the hep-
arin molecule for both inhibitor and protease. Since the initial
reaction velocities in each reaction system can be described by
the general rate equation for a random-order bireactant en-
zyme-catalyzed reaction (4, 19), it is concluded that the general
mechanism of action-of heparin in the reactions reported in the
present paper is similar.
MATERIALS AND METHODS
N -p-Tosyl-L-glyCyl-L-prolyl-L-arginine-p-nitroanilide (Tos-
GlyProArgNaN) was purchased from Boehringer Mannheim.
1,5-Dimethyl-1,5-diazaundecamethylene polymethobromide
(Polybrene) was purchased from Aldrich. Porcine mucosal hep-
arin (165 USP units/mg), essentially devoid of protein, was
generously provided by G. van Dedem and E. Coyne, Dio-
synth B. V. (Oss, The Netherlands). Concanavalin A-agarose was
purchased from Sigma.- Human a-thrombin (3,600 NIH units/
mg) and human antithrombin III were prepared as described
(5). Heparin cofactor II was purified to-homogeneity, as judged
by NaDodSO4/polyacrylamide gel electrophoresis, essentially
as described by Tollefsen and co-workers (17). Human factor Xa
was prepared as described (20).
Heparin Fractionation. Heparin was fractionated by gel fil-
tration and affinity chromatography. Approximately 250 mg of
heparin was applied to a Sephadex G-200 column (2.5 cm X 95
cm) previously equilibrated with 0.05 M Tris-HCl, pH 7.4/0.15
M NaCl. Material with an apparent molecular weight of 10,000-
13,000 was pooled and dialyzed against 0.02 M Tris-HCl, pH
7.0/0.05 M NaCl. Ten milligrams of dialyzed heparin was ap-
plied to a 1.1 cm X 4.0 cm column of concanavalin A-agarose
to which approximately 6 mg of heparin cofactor II or anti-
thrombin III had been noncovalently bound. The columns, which
were equilibrated with 0.02 M Tris-HCl, pH 7.0/0.05 M NaCl,
were washed with 25 ml of this buffer, and then bound heparin
was eluted with a 60 ml X 60 ml 0.05-0.5 M NaCl gradient in
0.02 M Tris-HCl (pH 7.0). Heparin activity was evaluated by
determining the rate of thrombin (2.0 nM) inhibition by an-
tithrombin III (20 nM) or heparin cofactor 11 (20 nM) in the
presence of heparin at 5.0 ng/ml. Heparin concentration (wt/
vol) was determined by uronic acid assay as described (21). To
obtain the relative specific activity of a given heparin fraction,
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FIG. 1. Kinetics of the heparin-catalyzed antithrombin III/thrombin reaction. The initial rate of thrombin inhibition by antithrombin III, in
the presence of heparin at 5.0 ng/ml, was determined. (A) Initial thrombin concentration = 2.0 nM. Data are plotted according to Eq. 5. (B) Initial
antithrombin III concentration = 500 nM. Data are plotted according to Eq. 3.
heparin was divided by the reaction velocity obtained in the
presence of unfractionated heparin (UF-heparin). Heparin with
the highest relative specific activity, which eluted from both
affinity columns between 0.3 M and 0.5 M NaCl, was pooled.
Heparin obtained from the heparin cofactor 1I/concanavalin A-
agarose column (HC-heparin) had a relative specific activity of
approximately 1.3 in both the antithrombin LII/thrombin re-
action and the heparin cofactor IL/thrombin reaction. Heparin
obtained from the antithrombin I1I/concanavalin A-agarose
column (AT-heparin) had a relative specific activity of approx-
imately 1.3 in the heparin cofactor II/thrombin reaction and of
approximately 3.0 in the antithrombin III/thrombin reaction.
The recovery of heparin, as determined by uronic acid and ac-
tivity assays, from both affinity columns was essentially 100%
(±4%). By weight, HC-heparin and AT-heparin constituted ap-
proximately 5% of the total heparin applied to the respective
columns. HC-heparin (1.0 ,ug/ml) and AT-heparin (1.0 ,ug/ml)
were incubated separately with thrombin (5 nM) for 30 min.
There was no detectable loss of thrombin activity under these
conditions, indicating that the fractionated heparins were not
contaminated by either heparin cofactor II or antithrombin III.
Inhibitor/Protease Reaction Velocity Determination. In-
hibitor/protease reaction measurements were made essentially
as described (4). All reactions were carried out in 0.1 M tri-
ethanolamine, pH 8.0/0.1 M NaCl/0.1% polyethylene glycol
(Mr, 6,000-7,500). The final protein and heparin concentra-
tions were varied. Reactions were initiated by adding the pro-
tease to a solution containing inhibitor and heparin. At timed
intervals after the addition of protease, samples were removed
and added to 0.1 M triethanolamine, pH 8.0/0.1 M NaCl/0. 1%
polyethylene glycol containing Polybrene at 0.5 mg/ml and
TosGlyProArgNaN. The final TosClyProArgNaN concentra-
tions were 0.15 mM and 0.3 mM in experiments measuring
thrombin and factor Xa inhibition, respectively. The hydrolysis
of TosClyProArgNaN was terminated by addition of acetic acid.
The amount of TosGlyProArgNaN hydrolyzed, determined by
absorbance at 400 nm, was proportional to the thrombin or fac-
tor Xa concentration. In all experiments, the initial inhibitor
concentration was significantly greater than the initial protease
concentration, such that the heparin-catalyzed antithrombin III/
thrombin reaction followed apparent pseudo-first-order kinet-
ics over the time course studied (4). The initial reaction velocity
(vi) was calculated by multiplying the observed pseudo-first-or-
der rate constant by the initial protease concentration.
General Inhibitor/Protease Reaction Velocity Equations.
In the present study, the heparin-catalyzed inhibitor/protease
reactions are considered to be analogous to a random-order bi-
reactant enzyme-catalyzed reaction (4, 19). The system is de-
scribed by the equilibria shown below.
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In this system, protease (P) and inhibitor (I) bind randomly to
heparin (H). Kp and K1 are the heparin-protease and heparin-
inhibitor dissociation constants, respectively, and k is the ap-
parent first-order rate constant for the rate-limiting step in
product formation. Kc is the dissociation constant for heparin
and the product of the reaction, the stable inhibitor-protease
complex (I-P). Assuming rapid equilibrium, the initial reaction
velocity, vi, is described by the following rate equation (19):
v.= k[H] x [P x [I]
Kp + [P] "K, + [I]
When the protease concentration is varied in the presence of
Table 1. Kinetic parameters for the heparin-catalyzed
antithrombin HI/thrombin reaction
KT, VTmax, V*ax) KAT, Vmax, V*max)
nM nM/min nM/min nM nM/min nM/min
UF-heparin 7.0 6.3 6.7 35 1.42 6.4
HC-heparin 7.0 6.9 7.4 35 1.70 7.7
AT-heparin 7.0 18.0 19.3 35 4.24 19.1
Kinetic parameters were determined from the data in Fig. 1.
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FIG. 2. Kinetics of the heparin-catalyzed heparin cofactor II/thrombin reaction. The initial rate of thrombin inhibition by heparin cofactor II,
in the presence of heparin at 10 ng/ml, was determined. (A) Initial thrombin concentration = 50 nM. Data are plotted according to Eq. 5. (B) Initial
heparin cofactor II concentration = 375 nM. Data are plotted according-to Eq. 3.
a fixed inhibitor concentration, the rate equation becomes
Ti=VPX [PVamaxxKd + [P]
and
I+~~~7- )~[3](VP~ x P] +mVa,[3
where VP a is the apparent maximum reaction velocity at sat-
uration with respect to the protease. Similarly, when the in-
hibitor concentration is varied in the presence of a fixed pro-
tease concentration,
Vi=Vn X, [] [4]mx
KI + [I]
and
-= (Vls X []) + Vl1[5]
where V' ax is the apparent maximum reaction velocity at sat-
uration with respect to inhibitor. The apparent maximum re-
action velocities, VP,, and V a,, are related to each other ac-
cording to the following:
Vmax =k[H] = VMIax Vmax ] , [6]
where V* ax is the maximum reaction velocity at saturation with
Table 2. Kinetic parameters for the heparin-catalyzed heparin
cofactor II/thrombin reaction
KT, Vmiax, Vmx) KHC, VX, V*nax,
nM nM/min nM/min. nM nM/min nM/min
UF-heparin 7.5 4.6 6.4 150 5.8 6.7
HC-heparin 7.5 6.0 8.4 150 7.4 8.5
AT-heparin 7.5 6.5 9.1 150 7.8 9.1
Kinetic parameters were determined from the data in Fig. 2.
respect to both inhibitor and protease. V* .a values calculated
from VI ar and VP ax values should be equivalent if Eq. 1 is a
[2] valid description of the reaction system.
RESULTS
The heparin-catalyzed antithrombin III/thrombin reaction ve-
locity was determined as a function of antithrombin III (Fig.
1A) and thrombin (Fig. 1B) concentrations. Apparent satura-
tion kinetics were obtained with the three heparin preparations
studied. The kinetic parameters, summarized in Table 1, in-
dicate that the three heparin preparations do not differ measur-
ably with respect to apparent heparin-thrombin and heparin-
antithrombin III binding affinities. The relative activities, as
indicated by the V*a values, did, however, differ. AT-heparin
had approximately three times the activity of UF-heparin. HG-
heparin activity was only slightly (1.3-fold) greater than the ac-
tivity of UF-heparin.
The heparin-catalyzed heparin cofactor II/thrombin reaction
velocity was determined as a function of heparin cofactor II (Fig.
2A) and thrombin (Fig. 2B) concentrations. Apparent satura-
tion kinetics were obtained with the three heparin preparations
studied. The kinetic parameters, summarized in Table 2, in-
dicate that the apparent heparin-thrombin and heparin-hep-
arin cofactor II binding affinities are similar for the three hep-
arin preparations studied. The relative specific activities of AT-
heparin and HC-heparin were also similar. Both heparins were
approximately 1.3-fold more active than UF-heparin.
The heparin-catalyzed antithrombin III/factor Xa reaction
velocity was determined as a function of factor Xa (Fig. 3) and
antithrombin III (data not shown) concentrations. Apparent-sat-
uration kinetics were obtained. The kinetic parameters- for the
three reactions studied are summarized-in. Table 3, where the
V*ax values are expressed in terms of maximum reaction ve-
locity per nanogram of AT-heparin.
DISCUSSION
Three different heparin-catalyzed inhibitor/protease reactions
were studied. In each reaction, the initial reaction velocity can
be described by the general rate equation for a random-order
t'AT62 Biochemistry: Griffith
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FIG. 3. Kinetics of the heparin-catalyzed antithrombin II/factor
Xa reaction. The initial rate offactorXa inhibition by antithrombin III,
in the presence ofAT-heparin at 15 ng/ml, was determined. The initial
antithrombin HI concentration was 500 nM. Data are plotted according
to Eq. 3.
bireactant enzyme-catalyzed reaction (4, 19).
The kinetic parameters for the three reactions studied were
dependent on the components of the reaction mixture (Table
3). The apparent binding affinity of antithrombin III for hep-
arin was, however, independent of the protease in the reaction
system. Similarly, the apparent binding affinity of thrombin for
heparin was independent of the inhibitor in the reaction sys-
tem. These results are consistent with the random-order bind-
ing of reactants to heparin. The apparent binding affinity of
antithrombin III for heparin differed significantly from the ap-
parent binding affinity of heparin for heparin cofactor II. These
results are compatible with the relative affinities of antithrom-
bin III and heparin cofactor II for heparin-agarose (17, 18). The
apparent binding affinity of thrombin for heparin differed sig-
nificantly from the apparent binding affinity of factor Xa for
heparin. These results are also compatible with the relative af-
finities of thrombin and factor Xa for heparin-agarose.
Heparin fractionation by affinity for antithrombin III had a
significant effect on the catalytic properties of heparin. The ki-
netic parameters for the antithrombin III/thrombin reaction
catalyzed by AT-heparin and UF-heparin differed, however,
only in terms of the V* ax values (Table 1). This result is con-
sistent with the expectation that AT-heparin is relatively free
of "inactive" heparin and should have a higher specific activity





III/thrombin il/thrombin II/factor Xa
Apparent Km
for inhibitor, nM 35 150 35
Apparent Km
for protease, nM 7.0 7.5 160
Apparent V*a
(nM/min)/ng 3.8 0.9 6.4
Kinetic parameters were determined for inhibitor/protease reac-
tionscatalyzedbyAT-heparin. V* values are normalizedtoAT-hepa-
rin at 1.0 ng/ml.
than UF-heparin. The heparin-antithrombin III dissociation
constant (KAT) values observed for AT-heparin and UF-heparin
would not be expected to differ since the kinetically deter-
mined KAT values reflect antithrombin III binding to "active"
heparin-i.e., heparin that can catalyze the antithrombin III/
thrombin reaction.
Heparin fractionation by affinity for heparin cofactor II had
a slight effect on the catalytic properties of heparin. The V* ax
values for the antithrombin III/thrombin and heparin cofactor
II/thrombin reactions catalyzed by HC-heparin were only about
30% higher than the V* a, values for the UF-heparin-catalyzed
reactions (Tables 1 and 2). Interestingly, if antithrombin III and
heparin cofactor II bind to the same oligosaccharide sequence
within the heparin molecule, AT-heparin, which has a 3-fold
higher specific activity (V* a value) than UF-heparin with re-
spect to the antithrombin III/thrombin reaction, should also
have a 3-fold higher specific activity than UF-heparin with re-
spect to the heparin cofactor II/thrombin reaction. The V*max
values for the heparin cofactor II/thrombin reaction catalyzed
by AT-heparin and HC-heparin were, however, similar (Table
2). This observation is taken as indirect evidence that the bind-
ing sites in the heparin molecule for antithrombin III and hep-
arin cofactor II are not identical.t
The apparent V*,,x value was higher for the AT-heparin-cat-
alyzed antithrombin III/factor Xa reaction than for the AT-hep-
arin-catalyzed antithrombin III/thrombin reaction (Table 3).
The lower heparin-catalyzed antithrombin III/factor Xa reac-
tion velocity, relative to the heparin-catalyzed antithrombin III/
thrombin reaction velocity, which was observed with nonsatu-
rating factor Xa concentrations (12), can be attributed, in part,
to the large difference between KXa and KT values (Table 3).
Differences in the heparin preparations used in the present and
previous (12) studies could also, in part, explain the observed
difference in reaction velocities.
The present study has shown that the kinetically determined
mechanism of action of heparin is similar for three different
heparin-catalyzed inhibitor/protease reactions. f Thrombin and
factor Xa were specifically chosen for study because several re-
ports have suggested that the mechanism of action of heparin
in catalyzing their reaction with antithrombin III is different
(12, 13). Although the present study explains this difference in
terms of simple heparin binding affinity differences, the bind-
ing orientation of the protease on the heparin molecule may
also be important in determining the reaction velocity. In this
regard, it is important to note that kinetics does not prove
chemical mechanisms. The working model described here for
the mechanism of action of heparin in catalyzing protease/in-
hibitor reactions appears to describe the kinetics of these re-
actions. The apparent antithrombin III-heparin and protease-
heparin binding affinities, determined kinetically, may not be
equivalent to the corresponding true dissociation constants.
Therefore, at present, it can be concluded that the binding of
both inhibitor and protease to heparin is one important aspect
of the catalytic mechanism of action of heparin, but more sub-
tle events are also likely to be important in determining the
overall reaction velocity.
t Heparin has been fractionated to obtain material that does not bind to
antithrombin III-agarose. This material was essentially devoid of ac-
tivity in terms of catalyzing the antithrombin III/thrombin reaction
but catalyzed the heparin cofactor II/thrombin reaction as effectively
as heparin, which bound tightly to antithrombin II-agarose (22).
t It has been found that the dermatan sulfate-catalyzed heparin cofactor
I/thrombin reaction is saturable with respect to both heparin cofactor
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